Format

Send to

Choose Destination
Int J Mol Sci. 2014 Dec 11;15(12):23024-41. doi: 10.3390/ijms151223024.

Anti-vascular endothelial growth factor therapy in breast cancer.

Author information

1
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark. tinakristensen@studmed.au.dk.
2
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark. malin.knutsson@studmed.au.dk.
3
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany. markus.wehland@med.ovgu.de.
4
Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C 8000, Denmark. britt@biomed.au.dk.
5
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark. dgg@biomed.au.dk.
6
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany. elisabeth.warnke@med.ovgu.de.
7
Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Nørrebrogade 44, Aarhus C 8000, Denmark. nm@clin.au.dk.

Abstract

Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate.

PMID:
25514409
PMCID:
PMC4284752
DOI:
10.3390/ijms151223024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center